Biotech Stocks Surge After FDA Allows uniQure AMT-130 Refiling

uniQure shares surged after the company said the U.S. Food and Drug Administration will allow it to refile for AMT-130 using three-year Phase 1/2 data, reversing a prior setback that had forced the Huntington’s disease gene therapy onto a longer path.

Coverage on June 17 said the stock jumped about 80% to 81% after the news, reflecting investor relief that the program may now move back toward a Biologics License Application rather than requiring a new final-stage study.

FDA reverses course

The latest development marks a sharp change from November 2025, when the FDA had said the available Phase 1/2 data were not sufficient and that uniQure would need another study. That earlier position had cast doubt on the timeline for AMT-130 and on whether the therapy could advance without restarting part of the development process.

According to the reporting, the agency’s new stance would allow uniQure to proceed with a filing based on the existing three-year Phase 1/2 data. That does not guarantee approval, but it does reopen a regulatory route that had appeared to be closed.

The change matters because a filing based on existing data could shorten the time needed to seek review if the company completes and submits the application and the FDA accepts it.

Why AMT-130 matters

AMT-130 is uniQure’s experimental gene therapy for Huntington’s disease, a progressive and fatal neurodegenerative disorder. The program has been one of the company’s most important assets because it sits at the center of its effort to reach commercialization.

The reported reversal also suggests the FDA may be showing greater flexibility on the program than it did last year. Analysts cited in coverage said the shift could improve expectations not only for uniQure, but also for other gene and cell therapy developers watching the case closely.

Market reaction and broader signal

The stock move did not stay confined to uniQure. Reporting said the rally spilled into broader biotech names as investors interpreted the FDA’s stance as a more permissive signal for the sector.

That reaction underscores how much is riding on the regulatory outcome. A path that preserves the existing data package could pull the program closer to market than the prior FDA position implied, even though the company still has to clear the next review steps.

What happens next

The immediate next milestone is a formal resubmission or preparation for one. uniQure has said the FDA will allow the refiling, but the company still needs to make the submission and wait for the agency’s response.

Investors will also be watching for any new FDA requirements, including whether the agency asks for additional analysis, timing commitments or other conditions tied to the resubmission.

For now, the key change is that uniQure has regained a credible filing path for AMT-130 using data it already has, after months in which the program faced a much tougher regulatory outlook.